Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Claude Rwigema

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
The Lancet. Oncology|September 4, 2025
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trialDaniel Ma, Katharine Price, Eric Moore, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2025
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025Timothy Gilligan, Daniel W Lin, Nabil Adra, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
The Lancet. Oncology|September 4, 2025
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trialDaniel Ma, Katharine Price, Eric Moore, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2025
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025Timothy Gilligan, Daniel W Lin, Nabil Adra, et al.
Pageof 3